Daré Bioscience, Inc.

Equities

DARE

US23666P1012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.3059 ^USD	+5.77%		+9.25%	-1.00%

Apr. 23	Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1	CI
Mar. 28	Transcript : Daré Bioscience, Inc., 2023 Earnings Call, Mar 28, 2024

Daré Bioscience, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023

August 10, 2023 at 08:00 am EDT

Daré Bioscience, Inc. reported earnings results for the second quarter ended June 30, 2023. For the second quarter, the company reported net loss was USD 8.76 million compared to net income of USD 0.413998 million a year ago. Basic loss per share from continuing operations was USD 0.1. Diluted loss per share from continuing operations was USD 0.1.

Latest news about Daré Bioscience, Inc.

Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1	Apr. 23	CI
Transcript : Daré Bioscience, Inc., 2023 Earnings Call, Mar 28, 2024	Mar. 28
Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024	Jan. 31	CI
Daré Bioscience, Inc. Announces Executive Changes	Jan. 26	CI
Daré Bioscience, Inc. Announces the Resignation of Lisa Walters-Hoffert as Chief Financial Officer	Jan. 26	CI
Dare Bioscience Says Chief Financial Officer Retiring, Chief Commercial Officer Has Resigned	Jan. 26	MT
Dare Bioscience, Inc. Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the Dare-Pdm1 Phase 1 Clinical Study	Dec. 20	CI
Dare Bioscience Obtains FDA Clearance for Phase 2 Trial of Potential Dyspareunia Treatment	Dec. 07	MT
Dare Bioscience, Inc. Announces FDA Clearance of Investigational New Drug Application for DARE-VVA1	Dec. 07	CI
Dare Bioscience, Inc. Announces Commencement of Phase 3 Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive	Dec. 04	CI
Dare Bioscience Extends Agreement With Premier Research to Advance Reproductive Health Portfolio	Nov. 20	MT
Dar Bioscience, Inc. and Premier Research International LLC Extend Strategic Partnership to Accelerate the Clinical Development of Dar's Novel Women's Health Programs	Nov. 20	CI
HC Wainwright Trims Price Target on Dare Bioscience to $6 From $7, Keeps Buy Rating	Nov. 10	MT
Transcript : Daré Bioscience, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Daré Bioscience, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	Nov. 09	CI
Dare Bioscience Says Additional Data Show Sildenafil Cream Improving Sexual Disorder Symptoms	Nov. 01	MT
Sector Update: Health Care Stocks Rise Late Afternoon	23-10-16	MT
Sector Update: Health Care Stocks Gaining Monday Afternoon	23-10-16	MT
Dare Bioscience Triggers $1.8 Million Milestone Payment from Organon With Xaciato's First Shipment	23-10-16	MT
Dare Bioscience to Get $4.5 Million Grant Funding Installment for Development of Contraceptive Technology	23-09-21	MT
Dare Bioscience to Raise $7 Million in Registered Direct Offering of Shares, Warrants	23-08-30	MT
Transcript : Daré Bioscience, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Daré Bioscience, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023	23-08-10	CI
Dare Bioscience Says Intravaginal Ring Showed Initial Efficacy in Treating Menopause Symptoms in Phase 1/2 Study	23-08-09	MT

Chart Daré Bioscience, Inc.

Duration

Period

More charts

Company Profile

Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Daré Bioscience, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.3059 USD

Average target price

4.667 USD

Spread / Average Target

+1,425.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DARÉ BIOSCIENCE, INC.	-1.00%	30.77M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research